Search the Community
Showing results for tags 'antibodies in lupus'.
Found 1 result
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus (SLE). The data suggest that targeting plasmacytoid DCs may be beneficial for patients with SLE, especially those with cutaneous manifestations. PubMed, J Clin Invest, 2019 Mar 1;129(3):1359-1371. (Also see Antibodies in Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.